ReviewFrontiers in immunology2026
The PANoptotic mosaic of rheumatoid arthritis: epitranscriptomic regulation, systemic relays, and precision death-mode editing.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic control of RNA methylation in rheumatoid arthritis: from synovial stress to pathogenic cellular adaptation.Frontiers in immunology · 2026Review
- Metabolic-epigenetic rewiring in rheumatoid arthritis: from pathogenic memory to precision restoration.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The persistence of difficult-to-treat rheumatoid arthritis (D2T-RA) underscores a fundamental disruption in synovial cell death homeostasis, transcending the limitations of conventional cytokine blockade. By integrating multi-omics, molecular imaging, and bio-responsive nanotechnologies, we characterized the PANoptosis framework-a synergistic programmed cell death (PCD) system converging apoptosis, pyroptosis, and necroptosis. Our findings reveal that environmental stressors perturb cellular antioxidant defenses, thereby precipitating PANoptosome assembly through mechanisms such as autoantibody-mediated biophysical triggers. Systemic crosstalk, spanning lung-derived inflammatory signals and gut metabolic rheostats, orchestrates synovial fate. Mechanistically, epitranscriptomic RNA methylation and dysregulated molecular switches within the PANoptosome drive inflammatory flares, while distal effects involve extracellular vesicle-mediated cartilage damage. Therapeutic interventions, such as bio-responsive nanoplatforms, effectively reprogram death modes toward inflammatory resolution. We conclude that PANoptosis is a central driver of RA pathogenesis, and its precision targeting via "death-mode editing" represents a paradigm shift from broad immunosuppression toward curative interventions. This work establishes a comprehensive PANoptic model and identifies actionable therapeutic avenues, offering transformative potential for the clinical management of RA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.